source
- FDA grants approval to Revolution Medicines' Rasonque for pancreatic cancerThe U.S. Food and Drug Administration has approved Rasonque, a new therapy from Revolution Medicines, for the treatment of pancreatic cancer. The decision follows data that showed the drug nearly…
- Novartis launches Phase 3 trial of IL-6 antibody to test cardiovascular benefit despite Novo's setbackNovartis announced it will begin a Phase 3 study evaluating its anti-IL-6 monoclonal antibody in patients at high cardiovascular risk. The trial aims to determine whether reducing inflammation thr…